[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100522581":3},{"organization":4,"outcomesModule":7,"designInfo":81,"detailedDescription":80,"studyPopulation":80,"armGroups":87,"interventions":132,"overallOfficials":146,"centralContacts":150,"locations":156,"responsibleParty":652,"collaborators":80,"id":654,"slug":655,"hasResults":656,"nctId":657,"briefTitle":658,"officialTitle":659,"acronym":80,"eligibilityCriteria":660,"healthyVolunteers":656,"sex":661,"minAge":662,"maxAge":80,"enrollmentInfo":663,"targetDuration":80,"studyType":666,"phases":667,"briefSummary":669,"conditions":670,"keywords":679,"overallStatus":335,"whyStopped":80,"lastUpdateSubmitDate":683,"lastUpdatePostDateStruct":684,"startDateStruct":687,"completionDateStruct":689,"leadSponsor":691,"locationsCount":692},{"fullName":5,"class":6},"AbbVie","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":22,"otherOutcomes":80},[9,13,16,19],{"measure":10,"description":11,"timeFrame":12},"Objective Response Rate (ORR)","ORR defined as percentage of participants with confirmed best overall response of confirmed partial response (PR) or better per investigator review according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.","Up to 36 Months",{"measure":14,"description":15,"timeFrame":12},"Number of Participants with Adverse Events (AEs)","An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.",{"measure":17,"description":18,"timeFrame":12},"Maximum Observed Concentration (Cmax) of ABBV-400 Conjugate","Cmax of ABBV-400 conjugate.",{"measure":20,"description":21,"timeFrame":12},"AUC from Time 0 to the End of Dosing Interval (AUCtau) of ABBV-400 Conjugate","AUCtau of ABBV-400 conjugate.",[23,26,29,32,35,38,41,44,47,50,53,56,59,62,65,68,71,74,77],{"measure":24,"description":25,"timeFrame":12},"Duration of Response (DOR) for Participants with Confirmed Complete Response (CR)\u002FPR","DOR is defined for participants achieving a confirmed PR or better as the time from the initial response of PR (or better) per investigator review according to RECIST 1.1 criteria to disease progression or death of any cause, whichever occurs earlier.",{"measure":27,"description":28,"timeFrame":12},"Clinical Benefit Rate","CBR is defined as the proportion of participants with a best overall response of stable disease at least 5 weeks post first dose, confirmed CR or PR per investigator review according to RECIST, version 1.1",{"measure":30,"description":31,"timeFrame":12},"Progression-free Survival (PFS)","PFS is defined as time from first study treatment to a documented disease progression according to RECIST, version 1.1, as determined by the investigator, or death due to any cause, whichever occurs earlier.",{"measure":33,"description":34,"timeFrame":12},"Overall Survival (OS)","OS is defined as time from first study treatment to death due to any cause.",{"measure":36,"description":37,"timeFrame":12},"Cmax of ABBV-400","Cmax of ABBV-400.",{"measure":39,"description":40,"timeFrame":12},"Time to Cmax (Tmax) of ABBV-400","Tmax of ABBV-400.",{"measure":42,"description":43,"timeFrame":12},"Area Under the Plasma Concentration-time Curve (AUC) for Total Antibody Concentration","AUC for total antibody concentration.",{"measure":45,"description":46,"timeFrame":12},"Total Antibody Drug Conjugate (ADC) Concentration","Total ADC concentration.",{"measure":48,"description":49,"timeFrame":12},"Plasma Concentrations of Unconjugated Topoisomerase 1 (Top1) Inhibitor Payload","Plasma concentrations of unconjugated Top1 inhibitor payload.",{"measure":51,"description":52,"timeFrame":12},"Antidrug Antibody (ADA)","Incidence and concentration of anti-drug antibodies.",{"measure":54,"description":55,"timeFrame":12},"Neutralizing Antidrug Antibody (nADA)","Incidence and concentration of neutralizing anti-drug antibodies.",{"measure":57,"description":58,"timeFrame":12},"Tmax of ABBV-400 Conjugate","Tmax of ABBV-400 conjugate.",{"measure":60,"description":61,"timeFrame":12},"Tmax of ABBV-400 Unconjugated","Tmax of ABBV-400 unconjugated.",{"measure":63,"description":64,"timeFrame":12},"Terminal Phase Elimination Half-Life (t1\u002F2) of ABBV-400 Conjugate","t1\u002F2 of ABBV-400 conjugate.",{"measure":66,"description":67,"timeFrame":12},"t1\u002F2 of ABBV-400 Unonjugated","t1\u002F2 of ABBV-400 unconjugated.",{"measure":69,"description":70,"timeFrame":12},"Volume of Distribution at Steady State (Vss) of ABBV-400 Conjugate","Vss of ABBV-400 conjugate.",{"measure":72,"description":73,"timeFrame":12},"Vss of ABBV-400 Unconjugated","Vss of ABBV-400 unconjugated.",{"measure":75,"description":76,"timeFrame":12},"Total Body Clearance at Steady State (CLss) of ABBV-400 Conjugate","CLss of ABBV-400 conjugate.",{"measure":78,"description":79,"timeFrame":12},"CLss of ABBV-400 Unconjugated","CLss of ABBV-400 unconjugated.",null,{"allocation":82,"interventionModel":83,"interventionModelDescription":80,"primaryPurpose":84,"observationalModel":80,"timePerspective":80,"maskingInfo":85},"NON_RANDOMIZED","PARALLEL","TREATMENT",{"masking":86,"maskingDescription":80,"whoMasked":80},"NONE",[88,94,98,102,106,110,114,118,122,127],{"label":89,"type":90,"description":91,"interventionNames":92},"Cohort 1: Hepatocellular Carcinoma (HCC)","EXPERIMENTAL","Participants with HCC will receive ABBV-400 for up to 3 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.",[93],"Drug: ABBV-400",{"label":95,"type":90,"description":96,"interventionNames":97},"Cohort 2: Pancreatic Ductal Adenocarcinoma (PDAC)","Participants with PDAC will receive ABBV-400 for up to 3 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.",[93],{"label":99,"type":90,"description":100,"interventionNames":101},"Cohort 3: Biliary Tract Cancers (BTC)","Participants with BTC will receive ABBV-400 for up to 3 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.",[93],{"label":103,"type":90,"description":104,"interventionNames":105},"Cohort 4: Esophageal Squamous Cell Carcinoma, (ESCC)","Participants with ESCC will receive ABBV-400 for up to 3 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.",[93],{"label":107,"type":90,"description":108,"interventionNames":109},"Cohort 5: Triple Negative Breast Cancer (TNBC)","Participants with TNBC will receive ABBV-400 for up to 3 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.",[93],{"label":111,"type":90,"description":112,"interventionNames":113},"Cohort 6: Hormone Receptor+\u002FHER2-breast Cancer (HR+\u002FHER2-BC)","Participants with HR+\u002FHER2-BC will receive ABBV-400 for up to 3 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.",[93],{"label":115,"type":90,"description":116,"interventionNames":117},"Cohort 7: Head and Neck Squamous-cell-carcinoma (HNSCC)","Participants with HNSCC will receive ABBV-400 for up to 3 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.",[93],{"label":119,"type":90,"description":120,"interventionNames":121},"Cohort 8: PROC\u002FPrimary Peritoneal\u002FFallopian Tube Cancer","Participants with Platinum Resistant High Grade Epithelial Ovarian Cancer (PROC)\u002Fprimary peritoneal\u002Ffallopian tube cancer will receive ABBV-400 for up to 3 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.",[93],{"label":123,"type":90,"description":124,"interventionNames":125},"Cohort 9: Drug-Drug Interaction","Participants with advanced or metastatic solid tumors will receive ABBV-400 and a strong CYP3A4 inhibitor (ITZ) for up to 3 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.",[93,126],"Drug: Itraconazole (ITZ)",{"label":128,"type":90,"description":129,"interventionNames":130},"Cohort 10: PROC\u002FPrimary Peritoneal\u002FFallopian Tube Cancer","Participants with PROC\u002Fprimary peritoneal\u002Ffallopian tube cancer will receive ABBV-400 in combination with bevacizumab for up to 3 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.",[93,131],"Drug: Bevacizumab",[133,138,142],{"type":134,"name":135,"description":136,"armGroupLabels":137,"otherNames":80},"DRUG","ABBV-400","Intravenous (IV) Infusion",[128,89,95,99,103,107,111,115,119,123],{"type":134,"name":139,"description":140,"armGroupLabels":141,"otherNames":80},"Itraconazole (ITZ)","Oral Solution",[123],{"type":134,"name":143,"description":144,"armGroupLabels":145,"otherNames":80},"Bevacizumab","IV Infusion",[128],[147],{"name":148,"affiliation":5,"role":149},"ABBVIE INC.","STUDY_DIRECTOR",[151],{"name":152,"role":153,"phone":154,"phoneExt":80,"email":155},"ABBVIE CALL CENTER","CONTACT","844-663-3742","abbvieclinicaltrials@abbvie.com",[157,171,181,191,200,210,220,226,236,246,255,265,275,285,295,304,314,324,333,348,358,370,380,392,402,410,419,428,440,446,451,460,465,470,474,485,496,506,516,526,532,538,550,560,568,577,583,589,595,604,613,625,634,643],{"facility":158,"status":159,"city":160,"state":161,"zip":162,"country":163,"countryCode":164,"cosmosGeoPoint":165,"geoPoint":170,"contacts":80},"City of Hope National Medical Center \u002FID# 258645","ACTIVE_NOT_RECRUITING","Duarte","California","91010","United States","US",{"type":166,"coordinates":167},"Point",[168,169],-117.97729,34.13945,{"lat":169,"lon":168},{"facility":172,"status":173,"city":174,"state":161,"zip":175,"country":163,"countryCode":164,"cosmosGeoPoint":176,"geoPoint":180,"contacts":80},"UCSF Medical Center - Mount Zion \u002FID# 257705","COMPLETED","San Francisco","94115",{"type":166,"coordinates":177},[178,179],-122.41942,37.77493,{"lat":179,"lon":178},{"facility":182,"status":173,"city":183,"state":184,"zip":185,"country":163,"countryCode":164,"cosmosGeoPoint":186,"geoPoint":190,"contacts":80},"University of Colorado Cancer Center - Cancer Clinical Trials Office \u002FID# 255128","Aurora","Colorado","80045-7158",{"type":166,"coordinates":187},[188,189],-104.83192,39.72943,{"lat":189,"lon":188},{"facility":192,"status":159,"city":193,"state":184,"zip":194,"country":163,"countryCode":164,"cosmosGeoPoint":195,"geoPoint":199,"contacts":80},"Sarah Cannon Research Institute at HealthONE - Denver \u002FID# 258926","Denver","80218",{"type":166,"coordinates":196},[197,198],-104.9847,39.73915,{"lat":198,"lon":197},{"facility":201,"status":159,"city":202,"state":203,"zip":204,"country":163,"countryCode":164,"cosmosGeoPoint":205,"geoPoint":209,"contacts":80},"Florida Cancer Specialists \u002FID# 261569","Sarasota","Florida","34232",{"type":166,"coordinates":206},[207,208],-82.53065,27.33643,{"lat":208,"lon":207},{"facility":211,"status":159,"city":212,"state":213,"zip":214,"country":163,"countryCode":164,"cosmosGeoPoint":215,"geoPoint":219,"contacts":80},"Northwestern University Feinberg School of Medicine \u002FID# 257378","Chicago","Illinois","60611-2927",{"type":166,"coordinates":216},[217,218],-87.65005,41.85003,{"lat":218,"lon":217},{"facility":221,"status":159,"city":212,"state":213,"zip":222,"country":163,"countryCode":164,"cosmosGeoPoint":223,"geoPoint":225,"contacts":80},"University of Chicago Medical Center \u002FID# 258197","60637",{"type":166,"coordinates":224},[217,218],{"lat":218,"lon":217},{"facility":227,"status":159,"city":228,"state":229,"zip":230,"country":163,"countryCode":164,"cosmosGeoPoint":231,"geoPoint":235,"contacts":80},"START Midwest \u002FID# 256581","Grand Rapids","Michigan","49546-7062",{"type":166,"coordinates":232},[233,234],-85.66809,42.96336,{"lat":234,"lon":233},{"facility":237,"status":159,"city":238,"state":239,"zip":240,"country":163,"countryCode":164,"cosmosGeoPoint":241,"geoPoint":245,"contacts":80},"Washington University-School of Medicine \u002FID# 257379","St Louis","Missouri","63110",{"type":166,"coordinates":242},[243,244],-90.19789,38.62727,{"lat":244,"lon":243},{"facility":247,"status":159,"city":248,"state":248,"zip":249,"country":163,"countryCode":164,"cosmosGeoPoint":250,"geoPoint":254,"contacts":80},"Memorial Sloan Kettering Cancer Center - New York - York Avenue \u002FID# 255132","New York","10065",{"type":166,"coordinates":251},[252,253],-74.00597,40.71427,{"lat":253,"lon":252},{"facility":256,"status":159,"city":257,"state":258,"zip":259,"country":163,"countryCode":164,"cosmosGeoPoint":260,"geoPoint":264,"contacts":80},"Duke Cancer Center \u002FID# 255129","Durham","North Carolina","27710",{"type":166,"coordinates":261},[262,263],-78.89862,35.99403,{"lat":263,"lon":262},{"facility":266,"status":159,"city":267,"state":268,"zip":269,"country":163,"countryCode":164,"cosmosGeoPoint":270,"geoPoint":274,"contacts":80},"Univ Hosp Cleveland \u002FID# 257706","Cleveland","Ohio","44106",{"type":166,"coordinates":271},[272,273],-81.69541,41.4995,{"lat":273,"lon":272},{"facility":276,"status":159,"city":277,"state":278,"zip":279,"country":163,"countryCode":164,"cosmosGeoPoint":280,"geoPoint":284,"contacts":80},"Lifespan Cancer Institute at Rhode Island Hospital \u002FID# 257693","Providence","Rhode Island","02903-4923",{"type":166,"coordinates":281},[282,283],-71.41283,41.82399,{"lat":283,"lon":282},{"facility":286,"status":173,"city":287,"state":288,"zip":289,"country":163,"countryCode":164,"cosmosGeoPoint":290,"geoPoint":294,"contacts":80},"MUSC Hollings Cancer Center \u002FID# 257935","Charleston","South Carolina","29425",{"type":166,"coordinates":291},[292,293],-79.93275,32.77632,{"lat":293,"lon":292},{"facility":296,"status":173,"city":297,"state":288,"zip":298,"country":163,"countryCode":164,"cosmosGeoPoint":299,"geoPoint":303,"contacts":80},"Prisma Health \u002FID# 257697","Greenville","29605",{"type":166,"coordinates":300},[301,302],-82.39401,34.85262,{"lat":302,"lon":301},{"facility":305,"status":159,"city":306,"state":307,"zip":308,"country":163,"countryCode":164,"cosmosGeoPoint":309,"geoPoint":313,"contacts":80},"Tennessee Oncology-Nashville Centennial \u002FID# 261568","Nashville","Tennessee","37203-1632",{"type":166,"coordinates":310},[311,312],-86.78444,36.16589,{"lat":312,"lon":311},{"facility":315,"status":173,"city":316,"state":317,"zip":318,"country":163,"countryCode":164,"cosmosGeoPoint":319,"geoPoint":323,"contacts":80},"MD Anderson Cancer Center \u002FID# 255131","Houston","Texas","77030",{"type":166,"coordinates":320},[321,322],-95.36327,29.76328,{"lat":322,"lon":321},{"facility":325,"status":159,"city":326,"state":317,"zip":327,"country":163,"countryCode":164,"cosmosGeoPoint":328,"geoPoint":332,"contacts":80},"Univ Texas HSC San Antonio \u002FID# 257708","San Antonio","78229-3901",{"type":166,"coordinates":329},[330,331],-98.49363,29.42412,{"lat":331,"lon":330},{"facility":334,"status":335,"city":326,"state":317,"zip":336,"country":163,"countryCode":164,"cosmosGeoPoint":337,"geoPoint":339,"contacts":340},"START-San Antonio","RECRUITING","78229",{"type":166,"coordinates":338},[330,331],{"lat":331,"lon":330},[341,345],{"name":342,"role":153,"phone":343,"phoneExt":80,"email":344},"HOPE Team","210-593-5250","hopeteam@startresearch.com",{"name":346,"role":347,"phone":80,"phoneExt":80,"email":80},"Dr. Papadopoulos","PRINCIPAL_INVESTIGATOR",{"facility":349,"status":173,"city":350,"state":351,"zip":352,"country":163,"countryCode":164,"cosmosGeoPoint":353,"geoPoint":357,"contacts":80},"Inova Schar Cancer Institute - Fairfax - Innovation Park Drive \u002FID# 262771","Fairfax","Virginia","22031",{"type":166,"coordinates":354},[355,356],-77.30637,38.84622,{"lat":356,"lon":355},{"facility":359,"status":173,"city":360,"state":361,"zip":362,"country":363,"countryCode":364,"cosmosGeoPoint":365,"geoPoint":369,"contacts":80},"Chris O'Brien Lifehouse \u002FID# 262765","Camperdown","New South Wales","2050","Australia","AU",{"type":166,"coordinates":366},[367,368],151.17642,-33.88965,{"lat":368,"lon":367},{"facility":371,"status":173,"city":372,"state":373,"zip":374,"country":363,"countryCode":364,"cosmosGeoPoint":375,"geoPoint":379,"contacts":80},"Austin Health \u002FID# 256635","Heidelberg","Victoria","3084",{"type":166,"coordinates":376},[377,378],145.06667,-37.75,{"lat":378,"lon":377},{"facility":381,"status":173,"city":382,"state":383,"zip":384,"country":385,"countryCode":386,"cosmosGeoPoint":387,"geoPoint":391,"contacts":80},"Rabin Medical Center. \u002FID# 256650","Petah Tikva","Central District","4941492","Israel","IL",{"type":166,"coordinates":388},[389,390],34.88747,32.08707,{"lat":390,"lon":389},{"facility":393,"status":173,"city":394,"state":395,"zip":396,"country":385,"countryCode":386,"cosmosGeoPoint":397,"geoPoint":401,"contacts":80},"The Chaim Sheba Medical Center \u002FID# 255731","Ramat Gan","Tel Aviv","5265601",{"type":166,"coordinates":398},[399,400],34.81065,32.08227,{"lat":400,"lon":399},{"facility":403,"status":173,"city":395,"state":395,"zip":404,"country":385,"countryCode":386,"cosmosGeoPoint":405,"geoPoint":409,"contacts":80},"Tel Aviv Sourasky Medical Center \u002FID# 258931","6423906",{"type":166,"coordinates":406},[407,408],34.78057,32.08088,{"lat":408,"lon":407},{"facility":411,"status":159,"city":412,"state":80,"zip":413,"country":385,"countryCode":386,"cosmosGeoPoint":414,"geoPoint":418,"contacts":80},"Rambam Health Care Campus \u002FID# 256649","Haifa","3109601",{"type":166,"coordinates":415},[416,417],34.99928,32.81303,{"lat":417,"lon":416},{"facility":420,"status":159,"city":421,"state":80,"zip":422,"country":385,"countryCode":386,"cosmosGeoPoint":423,"geoPoint":427,"contacts":80},"Hadassah Medical Center-Hebrew University \u002FID# 256655","Jerusalem","91120",{"type":166,"coordinates":424},[425,426],35.21633,31.76904,{"lat":426,"lon":425},{"facility":429,"status":173,"city":430,"state":431,"zip":432,"country":433,"countryCode":434,"cosmosGeoPoint":435,"geoPoint":439,"contacts":80},"NHO Nagoya Medical Center \u002FID# 261001","Nagoya","Aichi-ken","460-0001","Japan","JP",{"type":166,"coordinates":436},[437,438],136.90641,35.18147,{"lat":438,"lon":437},{"facility":441,"status":173,"city":430,"state":431,"zip":442,"country":433,"countryCode":434,"cosmosGeoPoint":443,"geoPoint":445,"contacts":80},"Aichi Cancer Center Hospital \u002FID# 256679","464-8681",{"type":166,"coordinates":444},[437,438],{"lat":438,"lon":437},{"facility":447,"status":159,"city":448,"state":449,"zip":450,"country":433,"countryCode":434,"cosmosGeoPoint":80,"geoPoint":80,"contacts":80},"National Cancer Center Hospital East \u002FID# 258934","Kashiwa-shi","Chiba","277-8577",{"facility":452,"status":159,"city":453,"state":453,"zip":454,"country":433,"countryCode":434,"cosmosGeoPoint":455,"geoPoint":459,"contacts":80},"Kyoto University Hospital \u002FID# 256680","Kyoto","606-8507",{"type":166,"coordinates":456},[457,458],135.75385,35.02107,{"lat":458,"lon":457},{"facility":461,"status":159,"city":462,"state":463,"zip":464,"country":433,"countryCode":434,"cosmosGeoPoint":80,"geoPoint":80,"contacts":80},"Shizuoka Cancer Center \u002FID# 257789","Sunto-gun","Shizuoka","411-8777",{"facility":466,"status":159,"city":467,"state":468,"zip":469,"country":433,"countryCode":434,"cosmosGeoPoint":80,"geoPoint":80,"contacts":80},"National Cancer Center Hospital \u002FID# 261136","Chuo-Ku","Tokyo","104-0045",{"facility":471,"status":159,"city":472,"state":468,"zip":473,"country":433,"countryCode":434,"cosmosGeoPoint":80,"geoPoint":80,"contacts":80},"The Cancer Institute Hospital Of JFCR \u002FID# 257788","Koto-ku","135-8550",{"facility":475,"status":173,"city":476,"state":80,"zip":477,"country":478,"countryCode":479,"cosmosGeoPoint":480,"geoPoint":484,"contacts":80},"Pan American Center for Oncology Trials - Rio Piedras \u002FID# 262903","Rio Piedras","00935","Puerto Rico","PR",{"type":166,"coordinates":481},[482,483],-66.04989,18.39745,{"lat":483,"lon":482},{"facility":486,"status":173,"city":487,"state":488,"zip":489,"country":490,"countryCode":80,"cosmosGeoPoint":491,"geoPoint":495,"contacts":80},"Inje University Haeundae Paik Hospital \u002FID# 260118","Busan","Busan Gwang Yeogsi","48108","South Korea",{"type":166,"coordinates":492},[493,494],129.03004,35.10168,{"lat":494,"lon":493},{"facility":497,"status":173,"city":498,"state":499,"zip":500,"country":490,"countryCode":80,"cosmosGeoPoint":501,"geoPoint":505,"contacts":80},"Gyeongsang National University Hospital \u002FID# 260408","Jinju","Gyeongsangnam-do","52727",{"type":166,"coordinates":502},[503,504],128.08472,35.19278,{"lat":504,"lon":503},{"facility":507,"status":173,"city":508,"state":509,"zip":510,"country":490,"countryCode":80,"cosmosGeoPoint":511,"geoPoint":515,"contacts":80},"Chungbuk National University Hospital \u002FID# 256698","Cheongju-si","North Chungcheong","28644",{"type":166,"coordinates":512},[513,514],127.48972,36.63722,{"lat":514,"lon":513},{"facility":517,"status":173,"city":518,"state":519,"zip":520,"country":490,"countryCode":80,"cosmosGeoPoint":521,"geoPoint":525,"contacts":80},"Seoul National University Hospital \u002FID# 255730","Seoul","Seoul Teugbyeolsi","03080",{"type":166,"coordinates":522},[523,524],126.9784,37.566,{"lat":524,"lon":523},{"facility":527,"status":173,"city":518,"state":519,"zip":528,"country":490,"countryCode":80,"cosmosGeoPoint":529,"geoPoint":531,"contacts":80},"Samsung Medical Center \u002FID# 258933","06351",{"type":166,"coordinates":530},[523,524],{"lat":524,"lon":523},{"facility":533,"status":173,"city":518,"state":519,"zip":534,"country":490,"countryCode":80,"cosmosGeoPoint":535,"geoPoint":537,"contacts":80},"Korea University Guro Hospital \u002FID# 256700","08308",{"type":166,"coordinates":536},[523,524],{"lat":524,"lon":523},{"facility":539,"status":173,"city":540,"state":541,"zip":542,"country":543,"countryCode":544,"cosmosGeoPoint":545,"geoPoint":549,"contacts":80},"Institut Catala d Oncologia - ICO - Badalona \u002FID# 263954","Badalona","Barcelona","08916","Spain","ES",{"type":166,"coordinates":546},[547,548],2.24741,41.45004,{"lat":548,"lon":547},{"facility":551,"status":173,"city":552,"state":553,"zip":554,"country":543,"countryCode":544,"cosmosGeoPoint":555,"geoPoint":559,"contacts":80},"Clinica Universidad de Navarra - Pamplona \u002FID# 256703","Pamplona","Navarre","31008",{"type":166,"coordinates":556},[557,558],-1.64323,42.81687,{"lat":558,"lon":557},{"facility":561,"status":173,"city":541,"state":80,"zip":562,"country":543,"countryCode":544,"cosmosGeoPoint":563,"geoPoint":567,"contacts":80},"Hospital HM Nou Delfos \u002FID# 263953","08023",{"type":166,"coordinates":564},[565,566],2.15899,41.38879,{"lat":566,"lon":565},{"facility":569,"status":159,"city":570,"state":80,"zip":571,"country":543,"countryCode":544,"cosmosGeoPoint":572,"geoPoint":576,"contacts":80},"Hospital General Universitario Gregorio Maranon \u002FID# 262816","Madrid","28007",{"type":166,"coordinates":573},[574,575],-3.70256,40.4165,{"lat":575,"lon":574},{"facility":578,"status":173,"city":570,"state":80,"zip":579,"country":543,"countryCode":544,"cosmosGeoPoint":580,"geoPoint":582,"contacts":80},"Clinica Universidad de Navarra - Madrid \u002FID# 264042","28027",{"type":166,"coordinates":581},[574,575],{"lat":575,"lon":574},{"facility":584,"status":159,"city":570,"state":80,"zip":585,"country":543,"countryCode":544,"cosmosGeoPoint":586,"geoPoint":588,"contacts":80},"Hospital Universitario Fundacion Jimenez Diaz \u002FID# 256702","28040",{"type":166,"coordinates":587},[574,575],{"lat":575,"lon":574},{"facility":590,"status":159,"city":570,"state":80,"zip":591,"country":543,"countryCode":544,"cosmosGeoPoint":592,"geoPoint":594,"contacts":80},"Hospital Universitario HM Sanchinarro \u002FID# 256701","28050",{"type":166,"coordinates":593},[574,575],{"lat":575,"lon":574},{"facility":596,"status":173,"city":597,"state":80,"zip":598,"country":543,"countryCode":544,"cosmosGeoPoint":599,"geoPoint":603,"contacts":80},"Hospital Quiron Malaga \u002FID# 263994","Málaga","29004",{"type":166,"coordinates":600},[601,602],-4.42034,36.72016,{"lat":602,"lon":601},{"facility":605,"status":173,"city":606,"state":80,"zip":607,"country":543,"countryCode":544,"cosmosGeoPoint":608,"geoPoint":612,"contacts":80},"Hospital Universitario Miguel Servet \u002FID# 256704","Zaragoza","50009",{"type":166,"coordinates":609},[610,611],-0.87734,41.65606,{"lat":611,"lon":610},{"facility":614,"status":159,"city":615,"state":616,"zip":617,"country":618,"countryCode":619,"cosmosGeoPoint":620,"geoPoint":624,"contacts":80},"E-DA Cancer Hospital \u002FID# 258880","Kaohsiung City","Kaohsiung","82445","Taiwan","TW",{"type":166,"coordinates":621},[622,623],120.31333,22.61626,{"lat":623,"lon":622},{"facility":626,"status":173,"city":627,"state":80,"zip":628,"country":618,"countryCode":619,"cosmosGeoPoint":629,"geoPoint":633,"contacts":80},"China Medical University Hospital \u002FID# 256712","Taichung","40447",{"type":166,"coordinates":630},[631,632],120.6839,24.1469,{"lat":632,"lon":631},{"facility":635,"status":173,"city":636,"state":80,"zip":637,"country":618,"countryCode":619,"cosmosGeoPoint":638,"geoPoint":642,"contacts":80},"National Taiwan University Hospital \u002FID# 256713","Taipei","100",{"type":166,"coordinates":639},[640,641],121.52639,25.05306,{"lat":641,"lon":640},{"facility":644,"status":173,"city":645,"state":80,"zip":646,"country":618,"countryCode":619,"cosmosGeoPoint":647,"geoPoint":651,"contacts":80},"Linkou Chang Gung Memorial Hospital \u002FID# 259420","Taoyuan City","333",{"type":166,"coordinates":648},[649,650],121.29696,24.99368,{"lat":650,"lon":649},{"type":653,"investigatorFullName":80,"investigatorTitle":80,"investigatorAffiliation":80,"oldNameTitle":80,"oldOrganization":80},"SPONSOR","100522581","phase-1-study-to-assess-adverse-events-and-change-in-disease-activity-in-adult-participants-with-select-advanced-solid-tumor-indications-receiving-intravenous-iv-abbv-400-100522581",false,"NCT06084481","Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400","A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications","Inclusion Criteria:\n\n* Laboratory values meeting the criteria laid out in the protocol.\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n* Documented diagnosis of locally advanced or metastatic hepatocellular carcinoma (HCC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancers (BTC), squamous cell carcinoma of the esophagus, (ESCC), triple negative breast cancer (TNBC), hormone receptor+\u002FHER2-breast cancer (HR+\u002FHER2-BC), head and neck squamous-cell-carcinoma (HNSCC), or Platinum Resistant High Grade Epithelial Ovarian Cancer (PROC)\u002Fprimary peritoneal\u002Ffallopian tube cancer (by World Health Organization \\[WHO\\] criteria). Participant meets the criteria for disease activity laid out in the protocol.\n\nExclusion Criteria:\n\n* Have received anticancer therapy including chemotherapy, radiation therapy, immunotherapy, biologic, or any investigational therapy within 28 days or 5 half-lives of the drug (whichever is shorter) prior to the first dose of ABBV-400. Palliative radiation therapy for bone, skin, or subcutaneous metastases with 10 fractions or less is permitted and not subject to a washout period.\n* Unresolved clinically significant AEs \\> Grade 1 from prior anticancer therapy.\n* History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD or pneumonitis, including but not limited to those listed in the protocol.\n* History of clinically significant, intercurrent lung-specific illnesses, including those laid out in the protocol.\n* Untreated brain or meningeal metastases (i.e., participants with history of metastases are eligible provided they do not require ongoing steroid treatment for cerebral edema and have shown clinical and radiographic stability for at least 14 days after definitive therapy). Participants may continue on antiepileptic therapy if required.\n* History of other active malignancy, with the exception of those laid out in the protocol.\n* Any autoimmune, connective tissue or inflammatory disorders with documented or suspicious pulmonary involvement at screening (i.e., rheumatoid arthritis, Sjogren's, sarcoidosis etc.), and prior pneumonectomy.","ALL","18 Years",{"count":664,"type":665},325,"ESTIMATED","INTERVENTIONAL",[668],"PHASE1","Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors.\n\nABBV-400 is an investigational drug being developed for the treatment of advanced solid tumors. Study doctors put the participants in groups called cohorts. Cohorts 1-8 receive ABBV-400 alone (monotherapy), cohort 9 receives ABBV-400 with a strong CYP3A3 inhibitor (ITZ), and cohort 10 receives ABBV-400 with bevacizumab. All cohorts are followed by a safety follow-up period. Approximately 325 adult participants with hepatocellular carcinoma (HCC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancers (BTC), esophageal squamous cell carcinoma (ESCC), triple negative breast cancer (TNBC), hormone receptor+\u002Fhuman epidermal growth factor receptor 2 negative (HER2-) breast cancer (hormone receptor-positive \\[HR+\\]\u002FHER2-breast cancer \\[BC\\]), head and neck squamous-cell-carcinoma (HNSCC), Platinum Resistant High Grade Epithelial Ovarian Cancer (PROC)\u002Fprimary peritoneal\u002Ffallopian tube cancer, or advanced solid tumors, will be enrolled in the study in approximately 54 sites worldwide.\n\nIn cohorts 1-8, participants with the following advanced solid tumor indications: HCC, PDAC, BTC, ESCC, TNBC, HR+\u002FHER2-BC, HNSCC, and PROC\u002Fprimary peritoneal\u002Ffallopian tube cancer will receive intravenous (IV) ABBV-400 monotherapy, in cohort 9 participants will receive IV ABBV-400 and an oral solution of ITZ, and in cohort 10 participants will receive IV ABBV-400 and IV bevacizumab, for up to 3 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.",[671,672,673,674,675,676,677,678],"Hepatocellular Carcinoma","Pancreatic Ductal Adenocarcinoma","Biliary Tract Cancers","Esophageal Squamous Cell Carcinoma","Triple Negative Breast Cancer","Hormone Receptor+\u002FHuman Epidermal Growth Factor Receptor 2 Negative Breast Cancer","Head and Neck Squamous-Cell Carcinoma","Platinum Resistant High Grade Epithelial Ovarian Cancer",[671,672,673,674,675,676,677,678,680,681,135,682],"Solid Tumors","Advanced Solid Tumors","bevacizumab","2026-08-21",{"date":685,"type":686},"2026-08-24","ACTUAL",{"date":688,"type":686},"2023-11-09",{"date":690,"type":665},"2027-09",{"name":5,"class":6},54]